401 related articles for article (PubMed ID: 15501750)
1. Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening.
Bhatia V; Sinha M; Luxon B; Garg N
Infect Immun; 2004 Nov; 72(11):6245-54. PubMed ID: 15501750
[TBL] [Abstract][Full Text] [Related]
2. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
3. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease.
Gupta S; Wan X; Zago MP; Sellers VC; Silva TS; Assiah D; Dhiman M; Nuñez S; Petersen JR; Vázquez-Chagoyán JC; Estrada-Franco JG; Garg NJ
PLoS Negl Trop Dis; 2013; 7(1):e2018. PubMed ID: 23350012
[TBL] [Abstract][Full Text] [Related]
4.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
5. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
6. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
7. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
Haolla FA; Claser C; de Alencar BC; Tzelepis F; de Vasconcelos JR; de Oliveira G; Silvério JC; Machado AV; Lannes-Vieira J; Bruna-Romero O; Gazzinelli RT; dos Santos RR; Soares MB; Rodrigues MM
Vaccine; 2009 Sep; 27(41):5644-53. PubMed ID: 19635607
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
9. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA
Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944
[TBL] [Abstract][Full Text] [Related]
10. Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.
Aparicio-Burgos JE; Zepeda-Escobar JA; de Oca-Jimenez RM; Estrada-Franco JG; Barbabosa-Pliego A; Ochoa-García L; Alejandre-Aguilar R; Rivas N; Peñuelas-Rivas G; Val-Arreola M; Gupta S; Salazar-García F; Garg NJ; Vázquez-Chagoyán JC
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003625. PubMed ID: 25853654
[TBL] [Abstract][Full Text] [Related]
11. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.
Silveira EL; Claser C; Haolla FA; Zanella LG; Rodrigues MM
Clin Vaccine Immunol; 2008 Aug; 15(8):1292-300. PubMed ID: 18579696
[TBL] [Abstract][Full Text] [Related]
12.
Trevisan RO; Santos MM; Desidério CS; Alves LG; de Jesus Sousa T; de Castro Oliveira L; Jaiswal AK; Tiwari S; Bovi WG; de Oliveira-Silva M; Costa-Madeira JC; Castellano LRC; Silva MV; Azevedo V; Rodrigues Junior V; Oliveira CJF; de Castro Soares S
Dis Markers; 2020; 2020():9130719. PubMed ID: 33488847
[TBL] [Abstract][Full Text] [Related]
13. From genome screening to creation of vaccine against Trypanosoma cruzi by use of immunoinformatics.
Teh-Poot C; Tzec-Arjona E; Martínez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Dumonteil E
J Infect Dis; 2015 Jan; 211(2):258-66. PubMed ID: 25070943
[TBL] [Abstract][Full Text] [Related]
14. Biolistic DNA vaccination against Trypanosoma infection.
Bryan M; Guyach S; Norris KA
Methods Mol Biol; 2013; 940():305-15. PubMed ID: 23104351
[TBL] [Abstract][Full Text] [Related]
15. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
16. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.
Boscardin SB; Kinoshita SS; Fujimura AE; Rodrigues MM
Infect Immun; 2003 May; 71(5):2744-57. PubMed ID: 12704149
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
[TBL] [Abstract][Full Text] [Related]
18. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
[TBL] [Abstract][Full Text] [Related]
19. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
20. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]